Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cellectis S.A. ADR
(NQ:
CLLS
)
2.400
UNCHANGED
Streaming Delayed Price
Updated: 2:25 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cellectis S.A. ADR
< Previous
1
2
3
Next >
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
December 28, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
December 22, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
December 13, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
December 01, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
November 10, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
November 10, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
November 03, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
November 03, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Third Quarter 2022 Financial Results
October 27, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
October 11, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
September 28, 2022
From
Cellectis Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.